Top 5 Stocks to Buy Now
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel Free CTNM Stock Alerts

Contineum Therapeutics (CTNM) Competitors

Contineum Therapeutics logo
$11.91 +0.29 (+2.50%)
Closing price 03:57 PM Eastern
Extended Trading
$11.92 +0.01 (+0.08%)
As of 07:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CTNM vs. BHVN, RAPP, AGIO, GENB, and QURE

Should you buy Contineum Therapeutics stock or one of its competitors? MarketBeat compares Contineum Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Contineum Therapeutics include Biohaven (BHVN), Rapport Therapeutics (RAPP), Agios Pharmaceuticals (AGIO), Generate Biomedicines (GENB), and uniQure (QURE). These companies are all part of the "pharmaceutical products" industry.

How does Contineum Therapeutics compare to Biohaven?

Contineum Therapeutics (NASDAQ:CTNM) and Biohaven (NYSE:BHVN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

Contineum Therapeutics has higher revenue and earnings than Biohaven. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Contineum Therapeutics$50M8.91-$59.98M-$1.95N/A
BiohavenN/AN/A-$738.82M-$5.67N/A

88.8% of Biohaven shares are owned by institutional investors. 7.9% of Contineum Therapeutics shares are owned by company insiders. Comparatively, 13.8% of Biohaven shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Contineum Therapeutics presently has a consensus target price of $20.00, suggesting a potential upside of 67.93%. Biohaven has a consensus target price of $22.27, suggesting a potential upside of 49.64%. Given Contineum Therapeutics' higher probable upside, equities analysts plainly believe Contineum Therapeutics is more favorable than Biohaven.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Contineum Therapeutics
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Biohaven
1 Sell rating(s)
5 Hold rating(s)
9 Buy rating(s)
2 Strong Buy rating(s)
2.71

In the previous week, Biohaven had 3 more articles in the media than Contineum Therapeutics. MarketBeat recorded 4 mentions for Biohaven and 1 mentions for Contineum Therapeutics. Biohaven's average media sentiment score of 0.45 beat Contineum Therapeutics' score of 0.00 indicating that Biohaven is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Contineum Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Biohaven
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Contineum Therapeutics has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market. Comparatively, Biohaven has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market.

Contineum Therapeutics' return on equity of -27.09% beat Biohaven's return on equity.

Company Net Margins Return on Equity Return on Assets
Contineum TherapeuticsN/A -27.09% -25.64%
Biohaven N/A -866.46%-137.99%

Summary

Biohaven beats Contineum Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Contineum Therapeutics compare to Rapport Therapeutics?

Contineum Therapeutics (NASDAQ:CTNM) and Rapport Therapeutics (NASDAQ:RAPP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

In the previous week, Rapport Therapeutics had 3 more articles in the media than Contineum Therapeutics. MarketBeat recorded 4 mentions for Rapport Therapeutics and 1 mentions for Contineum Therapeutics. Rapport Therapeutics' average media sentiment score of 1.62 beat Contineum Therapeutics' score of 0.00 indicating that Rapport Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Contineum Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Rapport Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Contineum Therapeutics has higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Contineum Therapeutics$50M8.91-$59.98M-$1.95N/A
Rapport Therapeutics$20M92.98-$111.48M-$2.60N/A

Contineum Therapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Rapport Therapeutics' return on equity of -24.78% beat Contineum Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Contineum TherapeuticsN/A -27.09% -25.64%
Rapport Therapeutics N/A -24.78%-23.44%

Contineum Therapeutics presently has a consensus target price of $20.00, indicating a potential upside of 67.93%. Rapport Therapeutics has a consensus target price of $58.83, indicating a potential upside of 51.32%. Given Contineum Therapeutics' higher probable upside, research analysts clearly believe Contineum Therapeutics is more favorable than Rapport Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Contineum Therapeutics
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Rapport Therapeutics
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.90

Summary

Rapport Therapeutics beats Contineum Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Contineum Therapeutics compare to Agios Pharmaceuticals?

Contineum Therapeutics (NASDAQ:CTNM) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

Contineum Therapeutics currently has a consensus target price of $20.00, suggesting a potential upside of 67.93%. Agios Pharmaceuticals has a consensus target price of $40.89, suggesting a potential upside of 14.60%. Given Contineum Therapeutics' higher possible upside, equities research analysts plainly believe Contineum Therapeutics is more favorable than Agios Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Contineum Therapeutics
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Agios Pharmaceuticals
1 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.45

Contineum Therapeutics has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

Contineum Therapeutics has higher earnings, but lower revenue than Agios Pharmaceuticals. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Contineum Therapeutics$50M8.91-$59.98M-$1.95N/A
Agios Pharmaceuticals$54.03M39.27-$412.78M-$7.25N/A

In the previous week, Agios Pharmaceuticals had 1 more articles in the media than Contineum Therapeutics. MarketBeat recorded 2 mentions for Agios Pharmaceuticals and 1 mentions for Contineum Therapeutics. Agios Pharmaceuticals' average media sentiment score of 0.88 beat Contineum Therapeutics' score of 0.00 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Contineum Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Agios Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Contineum Therapeutics has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -639.84%. Contineum Therapeutics' return on equity of -27.09% beat Agios Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Contineum TherapeuticsN/A -27.09% -25.64%
Agios Pharmaceuticals -639.84%-34.11%-31.66%

Summary

Contineum Therapeutics and Agios Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Contineum Therapeutics compare to Generate Biomedicines?

Contineum Therapeutics (NASDAQ:CTNM) and Generate Biomedicines (NASDAQ:GENB) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

In the previous week, Generate Biomedicines had 1 more articles in the media than Contineum Therapeutics. MarketBeat recorded 2 mentions for Generate Biomedicines and 1 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.00 equaled Generate Biomedicines'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Contineum Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Generate Biomedicines
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Contineum Therapeutics presently has a consensus price target of $20.00, suggesting a potential upside of 67.93%. Generate Biomedicines has a consensus price target of $25.40, suggesting a potential upside of 64.61%. Given Contineum Therapeutics' higher probable upside, research analysts clearly believe Contineum Therapeutics is more favorable than Generate Biomedicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Contineum Therapeutics
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Generate Biomedicines
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86

Generate Biomedicines' return on equity of 0.00% beat Contineum Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Contineum TherapeuticsN/A -27.09% -25.64%
Generate Biomedicines N/A N/A N/A

Generate Biomedicines has lower revenue, but higher earnings than Contineum Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Contineum Therapeutics$50M8.91-$59.98M-$1.95N/A
Generate Biomedicines$30.30M65.28N/AN/AN/A

Summary

Generate Biomedicines beats Contineum Therapeutics on 6 of the 8 factors compared between the two stocks.

How does Contineum Therapeutics compare to uniQure?

Contineum Therapeutics (NASDAQ:CTNM) and uniQure (NASDAQ:QURE) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

Contineum Therapeutics has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Contineum Therapeutics$50M8.91-$59.98M-$1.95N/A
uniQure$16.10M192.11-$198.97M-$3.48N/A

Contineum Therapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market. Comparatively, uniQure has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

Contineum Therapeutics currently has a consensus target price of $20.00, indicating a potential upside of 67.93%. uniQure has a consensus target price of $58.92, indicating a potential upside of 20.14%. Given Contineum Therapeutics' higher possible upside, analysts plainly believe Contineum Therapeutics is more favorable than uniQure.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Contineum Therapeutics
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
uniQure
1 Sell rating(s)
4 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.65

Contineum Therapeutics has a net margin of 0.00% compared to uniQure's net margin of -1,154.42%. Contineum Therapeutics' return on equity of -27.09% beat uniQure's return on equity.

Company Net Margins Return on Equity Return on Assets
Contineum TherapeuticsN/A -27.09% -25.64%
uniQure -1,154.42%-145.81%-27.15%

78.8% of uniQure shares are owned by institutional investors. 7.9% of Contineum Therapeutics shares are owned by insiders. Comparatively, 4.7% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, uniQure had 61 more articles in the media than Contineum Therapeutics. MarketBeat recorded 62 mentions for uniQure and 1 mentions for Contineum Therapeutics. uniQure's average media sentiment score of 0.52 beat Contineum Therapeutics' score of 0.00 indicating that uniQure is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Contineum Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
uniQure
23 Very Positive mention(s)
9 Positive mention(s)
17 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Contineum Therapeutics beats uniQure on 9 of the 16 factors compared between the two stocks.

Get Contineum Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CTNM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CTNM vs. The Competition

Export
MetricContineum TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$434.43M$3.45B$6.45B$12.39B
Dividend YieldN/A2.30%2.69%5.83%
P/E Ratio-6.1111.0721.0722.20
Price / Sales8.91334.82530.36110.15
Price / CashN/A128.5644.8254.51
Price / Book1.708.2910.796.50
Net Income-$59.98M$23.85M$3.56B$336.88M
7 Day Performance-3.95%5.21%1.67%-0.22%
1 Month Performance-14.07%2.19%0.43%0.77%
1 Year Performance189.08%60.99%32.84%31.57%

Contineum Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CTNM
Contineum Therapeutics
1.5803 of 5 stars		$11.91
+2.5%		$20.00
+67.9%		+144.1%$434.43M$50MN/A31
BHVN
Biohaven
2.9453 of 5 stars		$11.41
+2.9%		$22.27
+95.1%		+6.8%$1.72BN/AN/A239
RAPP
Rapport Therapeutics
3.0657 of 5 stars		$35.76
-0.2%		$58.83
+64.5%		+249.7%$1.71BN/AN/AN/A
AGIO
Agios Pharmaceuticals
2.8536 of 5 stars		$28.52
+1.4%		$41.44
+45.3%		+2.0%$1.70B$54.03MN/A390
GENB
Generate Biomedicines
N/A$13.31
+0.9%		$25.40
+90.9%		N/A$1.70B$30.30MN/A312

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CTNM) was last updated on 6/23/2026 by MarketBeat.com Staff.
From Our Partners
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
Porter flew 3,300 miles to investigate this system
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel